JP2020529431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529431A5 JP2020529431A5 JP2020505827A JP2020505827A JP2020529431A5 JP 2020529431 A5 JP2020529431 A5 JP 2020529431A5 JP 2020505827 A JP2020505827 A JP 2020505827A JP 2020505827 A JP2020505827 A JP 2020505827A JP 2020529431 A5 JP2020529431 A5 JP 2020529431A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- enterococcus
- pharmaceutical composition
- bacterial strain
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 21
- 230000001580 bacterial effect Effects 0.000 claims 17
- 241000194033 Enterococcus Species 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 108020004465 16S ribosomal RNA Proteins 0.000 claims 7
- 241000894006 Bacteria Species 0.000 claims 7
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 5
- 241000194030 Enterococcus gallinarum Species 0.000 claims 5
- 229960004397 cyclophosphamide Drugs 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 241000927512 Barnesiella Species 0.000 claims 3
- 241000193403 Clostridium Species 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 241000894007 species Species 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 210000000936 intestine Anatomy 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 230000000813 microbial effect Effects 0.000 claims 2
- 244000005706 microflora Species 0.000 claims 2
- 230000004108 pentose phosphate pathway Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000016261 weight loss Diseases 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- 241000701474 Alistipes Species 0.000 claims 1
- 241000204018 Anaeroplasma Species 0.000 claims 1
- 241001013579 Anaerotruncus Species 0.000 claims 1
- 241000606125 Bacteroides Species 0.000 claims 1
- NGHMDNPXVRFFGS-IUYQGCFVSA-N D-erythrose 4-phosphate Chemical compound O=C[C@H](O)[C@H](O)COP(O)(O)=O NGHMDNPXVRFFGS-IUYQGCFVSA-N 0.000 claims 1
- KTVPXOYAKDPRHY-SOOFDHNKSA-N D-ribofuranose 5-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O KTVPXOYAKDPRHY-SOOFDHNKSA-N 0.000 claims 1
- 241000194029 Enterococcus hirae Species 0.000 claims 1
- 241000662772 Flavonifractor Species 0.000 claims 1
- 241000509618 Hallella Species 0.000 claims 1
- 241001112693 Lachnospiraceae Species 0.000 claims 1
- 241000160321 Parabacteroides Species 0.000 claims 1
- 241000605861 Prevotella Species 0.000 claims 1
- 241000605947 Roseburia Species 0.000 claims 1
- 241001568331 Vampirovibrio Species 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- JDTUMPKOJBQPKX-GBNDHIKLSA-N sedoheptulose 7-phosphate Chemical compound OCC(=O)[C@@H](O)[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O JDTUMPKOJBQPKX-GBNDHIKLSA-N 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1712857.0 | 2017-08-10 | ||
| GBGB1712857.0A GB201712857D0 (en) | 2017-08-10 | 2017-08-10 | Compositions comprising bacterial strains |
| GB1800866.4 | 2018-01-19 | ||
| GBGB1800866.4A GB201800866D0 (en) | 2018-01-19 | 2018-01-19 | Compositions comprising bacterial strains |
| EP18183642 | 2018-07-16 | ||
| EP18183642.0 | 2018-07-16 | ||
| PCT/EP2018/071831 WO2019030411A1 (en) | 2017-08-10 | 2018-08-10 | COMPOSITIONS COMPRISING BACTERIAL STRAINS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020529431A JP2020529431A (ja) | 2020-10-08 |
| JP2020529431A5 true JP2020529431A5 (https=) | 2021-09-16 |
Family
ID=63524238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505827A Pending JP2020529431A (ja) | 2017-08-10 | 2018-08-10 | 細菌株を含む組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200237834A1 (https=) |
| EP (1) | EP3664824A1 (https=) |
| JP (1) | JP2020529431A (https=) |
| KR (1) | KR20200038970A (https=) |
| CN (1) | CN111246866A (https=) |
| AU (1) | AU2018312955A1 (https=) |
| BR (1) | BR112020002212A2 (https=) |
| CA (1) | CA3072013A1 (https=) |
| IL (1) | IL272491A (https=) |
| MA (1) | MA49982A (https=) |
| MX (1) | MX392976B (https=) |
| SG (1) | SG11202001174XA (https=) |
| TW (1) | TW201919674A (https=) |
| WO (1) | WO2019030411A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019180051A1 (en) | 2018-03-19 | 2019-09-26 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| TWI731279B (zh) * | 2018-11-21 | 2021-06-21 | 葡萄王生技股份有限公司 | 發酵乳桿菌gkf3、含其之組合物及改善精神失調之用途 |
| KR102623834B1 (ko) * | 2020-07-13 | 2024-01-12 | 서울대학교병원 | 에스트로겐을 포함하는 장내 미생물총 변화를 통한 남성의 대장암 예방 또는 치료용 조성물 |
| AU2022348603A1 (en) * | 2021-09-20 | 2024-02-29 | Hudson Institute of Medical Research | Biotherapeutic enterococcus isolates |
| CN117903980B (zh) * | 2024-01-05 | 2024-10-18 | 四川大学 | 一种海氏肠球菌及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9107305D0 (en) * | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| JPH08259450A (ja) * | 1995-03-17 | 1996-10-08 | Nichinichi Seiyaku Kk | インターフェロン産生増強剤 |
| DE102010013209A1 (de) * | 2010-03-29 | 2011-09-29 | Technische Universität München | Diarrhö-Prophylaktikum |
| EP2876167A1 (en) * | 2013-11-21 | 2015-05-27 | Institut Gustave Roussy | Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment |
| CN108513545B (zh) * | 2015-11-20 | 2020-11-03 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
| GB201520497D0 (en) * | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
-
2018
- 2018-08-10 MX MX2020001632A patent/MX392976B/es unknown
- 2018-08-10 AU AU2018312955A patent/AU2018312955A1/en not_active Abandoned
- 2018-08-10 SG SG11202001174XA patent/SG11202001174XA/en unknown
- 2018-08-10 JP JP2020505827A patent/JP2020529431A/ja active Pending
- 2018-08-10 WO PCT/EP2018/071831 patent/WO2019030411A1/en not_active Ceased
- 2018-08-10 MA MA049982A patent/MA49982A/fr unknown
- 2018-08-10 KR KR1020207006523A patent/KR20200038970A/ko not_active Ceased
- 2018-08-10 CA CA3072013A patent/CA3072013A1/en active Pending
- 2018-08-10 TW TW107128096A patent/TW201919674A/zh unknown
- 2018-08-10 CN CN201880055780.6A patent/CN111246866A/zh active Pending
- 2018-08-10 EP EP18765808.3A patent/EP3664824A1/en not_active Withdrawn
- 2018-08-10 BR BR112020002212-8A patent/BR112020002212A2/pt not_active IP Right Cessation
-
2020
- 2020-02-05 IL IL272491A patent/IL272491A/en unknown
- 2020-02-07 US US16/784,958 patent/US20200237834A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fong et al. | Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer | |
| Liu et al. | The microbiome in inflammatory bowel diseases: from pathogenesis to therapy | |
| JP2020529431A5 (https=) | ||
| US10155015B2 (en) | Probiotic compositions for use in the treatment of bowel diseases | |
| Möndel et al. | Probiotic E. coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans | |
| JP2019163267A5 (https=) | ||
| Kim et al. | Lactobacillus plantarum CBT LP3 ameliorates colitis via modulating T cells in mice | |
| US12478652B2 (en) | Bacteriophage therapy | |
| Rachmilewitz et al. | Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis | |
| JP2019048857A5 (https=) | ||
| JP2019135254A5 (https=) | ||
| US11959067B2 (en) | Bifidobacterium lactis strain for preventing or treating colitis and method for preventing or alleviating colitis | |
| AU2019379234B2 (en) | Strains, composition and method of use | |
| JP2021523895A5 (https=) | ||
| JP2024523900A (ja) | 代謝性疾患の予防及び治療のためのラクトバチルスファーメンタム菌株及び制御性ｔ細胞の併用投与用途 | |
| Zeng et al. | Lactobacillus kefiranofaciens JKSP109 and Saccharomyces cerevisiae JKSP39 isolated from Tibetan kefir grain co-alleviated AOM/DSS induced inflammation and colorectal carcinogenesis | |
| JP2020529431A (ja) | 細菌株を含む組成物 | |
| Lazarenko et al. | Imunobiotics are the novel biotech drugs with antibacterial and immunomodulatory properties | |
| CA3145904A1 (en) | Compositions comprising bacterial strains | |
| Suresh et al. | Safety concerns of Probiotic use: A review | |
| Ye et al. | Faecal microbiota transplantation for eradicating Helicobacter pylori infection: clinical practice and theoretical postulation | |
| Tanriover et al. | Use of probiotics in various diseases: Evidence and promises | |
| Sanmillán et al. | Primary lumbar epidural abscess without spondylodiscitis caused by Fusobacterium necrophorum diagnosed by 16S rRNA PCR | |
| WO2013079994A1 (en) | Lactobacillus paracasei subsp. paracasei, as an agent for inhibiting listeria monocytogenes in vivo infection | |
| Feret et al. | Manipulation of the gut microbiota: probiotics and fecal microbiota transplantation as a treatment option for recurrent Clostridium difficile infection |